International Healthcare & Biotech Media
Insights into China innovative drugs, oncology breakthroughs, and international patient care.
26 Articles
2026-07-11
From medical record review and hospital matching to travel coordination and long-term follow-up, DengYueMed provides one-stop cross-border medical services that help international patients access China's high-quality healthcare resources.
2026-07-10
Landmark clinical evidence demonstrates that BNCT can dramatically improve progression-free survival for recurrent high-grade meningioma. Combined with China's rapid advances in accelerator-based BNCT systems, boron drugs, and national policy support, BNCT is emerging as one of the most promising precision radiotherapy technologies.
2026-07-09
Advanced drug delivery systems are reshaping pharmaceutical innovation by improving targeting, bioavailability, patient adherence, and long-term therapeutic outcomes. This article reviews six major drug delivery technologies driving China's next generation of innovative medicines.
2026-07-09
This article analyzes the worldwide accessibility of spinal muscular atrophy (SMA) therapies, examining treatment advances, healthcare disparities, reimbursement systems, supply chain challenges, and future trends toward equitable access for rare disease patients.
2026-07-03
As innovative drug R&D and precision medicine accelerate, drug approval speed is becoming a critical factor for international patients, shifting the focus from hospital reputation to rapid access to life-saving therapies.
2026-06-26
A comprehensive review of perioperative antibiotic prophylaxis, including surgical indications, antibiotic selection, administration timing, duration control, common misconceptions, and future trends in antimicrobial stewardship.
2026-06-22
Discover the five leading Chinese AI drug discovery companies transforming pharmaceutical innovation through artificial intelligence, generative AI, robotics, and computational biology. From XtalPi and Insilico Medicine to BioMap and Galixir, China's AI-powered biotech sector is rapidly becoming a major force in global drug development.
2026-06-18
PROTAC technology is transforming drug discovery by shifting the focus from inhibiting disease proteins to eliminating them entirely. Learn how targeted protein degradation could reshape the future of precision medicine.
2026-06-15
As healthcare resources expand into underserved regions worldwide, pharmaceutical companies face both significant opportunities and complex challenges in improving medicine accessibility, strengthening supply chains, and supporting healthcare equity.
2026-06-12
Drug repurposing is reshaping pharmaceutical markets worldwide. Discover how new indication approvals affect drug accessibility, patient demand, supply chain planning, and global healthcare delivery.
2026-06-12
Despite advances in modern medicine, pediatric drug shortages remain a global challenge. Explore the barriers to pediatric drug development, rare disease treatment access, and the future of pediatric healthcare.
2026-06-09
Off-label drug use has become increasingly common in oncology, rare diseases, pediatrics, and precision medicine. Understanding its benefits, risks, and regulatory framework can help patients make more informed treatment decisions.
2026-06-09
Understanding overseas medical costs, international health insurance, reimbursement rules, and strategies to reduce financial burdens when seeking treatment abroad.
2026-06-08
With advanced cardiovascular technologies, experienced specialists, innovative therapies, and competitive treatment costs, China is becoming an increasingly attractive destination for international patients seeking heart disease treatment.
2026-06-08
Advances in gene therapy, RNA-targeted therapies, and enzyme replacement treatments are transforming rare disease care worldwide. Learn how international healthcare services are helping patients access innovative therapies and global medical resources.
2026-06-05
At ASCO 2026, 13 studies from 12 Chinese biopharma companies were selected for Plenary and Late-Breaking sessions, highlighting China's growing influence in global oncology innovation through PD-1/VEGF bispecific antibodies, IO 2.0 therapies, and next-generation bispecific ADCs.
2026-06-05
China's healthcare innovation sector is expanding rapidly, bringing new opportunities for patients to access innovative medicines, cell and gene therapies, precision medicine, and cutting-edge clinical research.
2026-06-04
CAR-T therapy is transforming cancer treatment, but costs can vary dramatically between countries, hospitals, and products. Learn what drives the price differences and how patients can make informed decisions.
2026-06-04
As cross-border healthcare becomes increasingly common, patients often rely on medical facilitators to navigate complex healthcare systems. Learn how to evaluate international healthcare service providers and why China is becoming a growing destination for medical treatment.
2026-06-04
As global medical resources continue to integrate, more and more patients are seeking cross-border medical services. This article outlines the process of booking foreign hospitals, preparing medical records, and planning the entire overseas medical journey.
2026-06-02
Learn which international health insurance providers are accepted by Chinese hospitals, how direct billing works, and what overseas patients should know before seeking medical treatment in China.
2026-06-01
China's healthcare system is attracting more international patients through precision medicine, innovative therapies, efficient care pathways, and cost advantages, accelerating the growth of medical tourism and cross-border healthcare.
2026-05-29
As GLP-1 demand explodes globally, China is rapidly becoming one of the world’s most important peptide manufacturing hubs.
2026-05-28
As global demand for GLP-1 therapies surges, the peptide API industry is rapidly transitioning from small-scale synthesis to industrialized manufacturing.
2026-05-21
China’s biopharmaceutical industry is entering a new phase driven by policy reform, innovation, and global expansion.
2026-05-20
China’s innovative drugs sector is accelerating global collaboration through policy support, clinical progress, and expanding outbound licensing activity.